Home> Products> postprandial hyperglycemia

{ "products": [ { "_id": "6a1974914d580c75a3c81fba", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nateglinide 60mg", "description": "Managing blood sugar levels is one of the most important steps in living a healthy life with diabetes. Nateglinide 60mg Tablets are commonly prescribed to help people with Type 2 Diabetes Mellitus maintain better glucose control, especially after meals. This medicine belongs to a class of drugs known as meglitinides, which help the pancreas release insulin quickly after eating.\n\nIf you are searching for a reliable medication to support post-meal sugar control, Nateglinide 60mg Tablets may be an effective option recommended by healthcare professionals. In this detailed guide, you will learn how Nateglinide works, its uses, benefits, dosage information, side effects, precautions, and why it is widely used in diabetes management.\n\nWhat Are Nateglinide 60mg Tablets?\n\nNateglinide 60mg Tablets are oral anti-diabetic medicines used to treat Type 2 Diabetes Mellitus. They are specifically designed to control the rise in blood sugar levels that occurs after meals.\n\nUnlike some diabetes medicines that work throughout the day, Nateglinide acts quickly and for a shorter duration. This helps mimic the body's natural insulin response after eating.\n\nDoctors often prescribe Nateglinide along with a healthy diet, regular exercise, and lifestyle changes to achieve optimal diabetes control.\n\nComposition of Nateglinide 60mg Tablets\n\nEach tablet contains:\n\nNateglinide – 60mg\n\nThis active ingredient stimulates the pancreas to release insulin immediately after meals, helping reduce postprandial blood sugar spikes.\n\nHow Does Nateglinide 60mg Work?\n\nNateglinide belongs to the meglitinide class of anti-diabetic medicines. It works by stimulating the beta cells of the pancreas to release insulin quickly after food intake.\n\nMechanism of Action\nHelps the pancreas release insulin rapidly\nControls blood sugar rise after meals\nImproves glucose metabolism\nReduces post-meal hyperglycemia\nHelps maintain overall glycemic control\n\nBecause it acts quickly, Nateglinide is usually taken before meals for maximum effectiveness.\n\nUses of Nateglinide 60mg Tablets\n1. Treatment of Type 2 Diabetes Mellitus\n\nThe primary use of Nateglinide 60mg Tablets is to manage blood sugar levels in adults with Type 2 Diabetes.\n\n2. Post-Meal Sugar Control\n\nIt is especially effective in controlling sudden blood sugar spikes that occur after eating.\n\n3. Combination Therapy\n\nDoctors may prescribe Nateglinide with:\n\nMetformin\nInsulin sensitizers\nOther anti-diabetic medications\n4. Lifestyle-Based Diabetes Management\n\nNateglinide works best when combined with:\n\nBalanced diet\nRegular physical activity\nWeight management\nHealthy lifestyle habits\nBenefits of Nateglinide 60mg Tablets\nFast Action After Meals\n\nOne of the biggest advantages of Nateglinide is its rapid onset of action. It begins working quickly after intake, helping manage post-meal glucose spikes effectively.\n\nBetter Blood Sugar Control\n\nConsistent use can help:\n\nLower blood sugar levels\nImprove HbA1c levels\nReduce fluctuations in glucose levels\nFlexible Meal-Time Dosing\n\nSince it is taken before meals, patients may find it easier to adjust according to their eating schedule.\n\nLower Risk of Long-Term Diabetes Complications\n\nGood blood sugar management may reduce the risk of:\n\nNerve damage\nKidney problems\nVision issues\nHeart disease\nSupports Healthy Daily Living\n\nBy controlling sugar levels efficiently, Nateglinide helps patients maintain better energy and overall wellness.\n\nWhy Doctors Prescribe Nateglinide 60mg Tablets\n\nHealthcare professionals commonly prescribe Nateglinide because it offers:\n\nQuick insulin release\nEffective post-meal sugar control\nConvenient dosing\nGood compatibility with other diabetes medications\nImproved patient compliance\n\nIt is especially beneficial for patients who experience high blood sugar after meals despite diet control.\n\nDosage and Administration\nRecommended Dosage\n\nThe dosage depends on:\n\nBlood sugar levels\nMedical history\nOther medications\nDoctor’s recommendation\nGeneral Instructions\nUsually taken 1 to 30 minutes before meals\nSwallow with water\nDo not skip meals after taking the tablet\nFollow your doctor’s prescribed schedule carefully\n\nIf a meal is skipped, the dose may also need to be skipped to avoid low blood sugar.\n\nWho Should Use Nateglinide 60mg Tablets?\n\nNateglinide may be recommended for:\n\nAdults with Type 2 Diabetes\nPatients needing postprandial glucose control\nIndividuals not adequately controlled through diet and exercise alone\n\nHowever, it should only be used under medical supervision.\n\nWho Should Avoid Nateglinide?\n\nAvoid using Nateglinide without consulting a healthcare provider if you have:\n\nType 1 Diabetes\nSevere liver disease\nDiabetic ketoacidosis\nAllergy to Nateglinide\nFrequent hypoglycemia episodes\n\nPregnant and breastfeeding women should consult their doctor before use.\n\nSide Effects of Nateglinide 60mg Tablets\n\nLike all medicines, Nateglinide may cause some side effects. Most are mild and manageable.\n\nCommon Side Effects\nLow blood sugar (hypoglycemia)\nDizziness\nHeadache\nWeakness\nSweating\nTremors\nStomach discomfort\nSerious Side Effects\n\nSeek medical attention if you experience:\n\nSevere allergic reactions\nDifficulty breathing\nSevere hypoglycemia\nUnusual fatigue\nYellowing of skin or eyes\nSymptoms of Low Blood Sugar\n\nBecause Nateglinide increases insulin release, low blood sugar may occur, especially if meals are skipped.\n\nCommon Symptoms Include:\nHunger\nShaking\nFast heartbeat\nSweating\nConfusion\nBlurred vision\n\nKeep glucose tablets or sugary snacks available in case of sudden hypoglycemia.\n\nPrecautions While Using Nateglinide 60mg Tablets\nFollow a Proper Diet\n\nMedication alone is not enough. A diabetes-friendly diet is essential for effective glucose control.\n\nExercise Regularly\n\nPhysical activity helps improve insulin sensitivity and overall health.\n\nMonitor Blood Sugar Levels\n\nRegular glucose monitoring helps track treatment effectiveness.\n\nAvoid Alcohol\n\nAlcohol may increase the risk of low blood sugar.\n\nInform Your Doctor About Other Medicines\n\nSome medications may interact with Nateglinide and affect blood sugar levels.\n\nDrug Interactions\n\nNateglinide may interact with:\n\nInsulin\nMetformin\nBeta-blockers\nAntifungal medicines\nSteroids\nCertain antibiotics\n\nAlways inform your healthcare provider about all medications and supplements you use.\n\nStorage Instructions\n\nStore Nateglinide 60mg Tablets:\n\nIn a cool and dry place\nAway from direct sunlight\nBelow recommended room temperature\nOut of reach of children\n\nDo not use expired medicines.\n\nLifestyle Tips for Better Diabetes Management\n\nTo achieve the best results with Nateglinide:\n\nEat meals on time\nReduce sugar intake\nStay physically active\nMaintain healthy body weight\nDrink enough water\nAvoid smoking\nGet regular health checkups\n\nCombining medication with healthy habits can significantly improve diabetes control.\n\nFrequently Asked Questions (FAQs)\nCan Nateglinide 60mg Tablets cure diabetes?\n\nNo, Nateglinide helps manage blood sugar levels but does not cure diabetes.\n\nWhen should I take Nateglinide?\n\nIt is generally taken before meals as directed by your doctor.\n\nCan I take Nateglinide with other diabetes medicines?\n\nYes, doctors often prescribe it with other anti-diabetic medications depending on individual needs.\n\nWhat happens if I miss a dose?\n\nIf you skip a meal, you may need to skip the dose. Consult your doctor for guidance.\n\nIs Nateglinide safe for long-term use?\n\nIt can be used long-term under proper medical supervision and regular monitoring.\n\nConclusion\n\nNateglinide 60mg Tablets are an effective solution for managing post-meal blood sugar spikes in patients with Type 2 Diabetes Mellitus. With its rapid action and flexible dosing schedule, it helps improve glucose control and supports healthier daily living.\n\nWhen combined with proper diet, exercise, and regular monitoring, Nateglinide can play an important role in long-term diabetes management. Always use this medication exactly as prescribed by your healthcare professional for the best results and safety.", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2432, "imageuri": "https://productimages.withfloats.com/actual/6a1974a2e30ab7df920848be.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a1974a2e30ab7df920848be.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-05-29T11:12:17.589Z", "updatedon": "2026-05-29T11:15:43.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/nateglinide-60mg/2432", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NATIGLUMIDE 60", "category": "DIABETIC RANGE", "tags": [ "Nateglinide 60mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "698d91909e3c03f732124005", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Remogliflozin Etabonate Tablets 100 mg", "description": "REMOFLOZIN 100 is an advanced oral antidiabetic medication containing Remogliflozin Etabonate 100 mg as its active pharmaceutical ingredient. This innovative formulation represents a significant breakthrough in the management of Type 2 Diabetes Mellitus, offering patients a novel mechanism of action that works independently of insulin secretion or insulin sensitivity. REMOFLOZIN 100 belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitors class of medications, which has revolutionized diabetes management by targeting glucose reabsorption in the kidneys rather than affecting pancreatic function or peripheral glucose utilization.\nDeveloped through rigorous scientific research and clinical trials, REMOFLOZIN 100 provides diabetic patients with an effective therapeutic option that not only helps control blood sugar levels but also offers additional cardiovascular and metabolic benefits. Each tablet is precisely formulated to deliver consistent and reliable glycemic control, making it an essential component in the comprehensive management of Type 2 Diabetes.\nHow REMOFLOZIN 100 Works\nThe mechanism of action of REMOFLOZIN 100 is both unique and highly effective. Under normal physiological conditions, the kidneys filter glucose from the blood, but the SGLT2 proteins in the proximal renal tubules reabsorb approximately 90% of this filtered glucose back into the bloodstream. In diabetic patients, this reabsorption continues even when blood glucose levels are elevated, perpetuating hyperglycemia.\nRemogliflozin Etabonate works by selectively inhibiting the SGLT2 proteins in the kidneys, thereby reducing glucose reabsorption and increasing urinary glucose excretion. This insulin-independent mechanism allows the body to eliminate excess glucose naturally through urine, leading to sustained reductions in blood glucose levels. The medication typically begins working within hours of administration, with maximum therapeutic effects observed within several weeks of consistent use.\nPrimary Uses and Indications\nREMOFLOZIN 100 is primarily indicated for:\nManagement of Type 2 Diabetes Mellitus: As monotherapy in patients who cannot tolerate metformin or for whom metformin is contraindicated, and as combination therapy with other antidiabetic agents including metformin, sulfonylureas, or insulin when existing treatment regimens fail to achieve adequate glycemic control.\nGlycemic Control Optimization: For patients requiring additional blood sugar management beyond diet and exercise modifications, REMOFLOZIN 100 helps reduce both fasting plasma glucose and postprandial glucose levels.\nAdjunct to Lifestyle Modifications: The medication works synergistically with dietary modifications and regular physical activity to achieve comprehensive diabetes management and reduce the risk of long-term diabetic complications.\nKey Benefits of REMOFLOZIN 100\nSuperior Glycemic Control\nREMOFLOZIN 100 demonstrates significant efficacy in reducing HbA1c levels, typically achieving reductions of 0.5% to 1.0% when used as monotherapy and even greater reductions when combined with other antidiabetic medications. This improvement in long-term glucose control translates to reduced risk of microvascular complications, including diabetic retinopathy, nephropathy, and neuropathy.\nWeight Management Support\nUnlike many traditional antidiabetic medications that may cause weight gain, REMOFLOZIN 100 is associated with modest weight loss, typically ranging from 2 to 4 kilograms over several months of treatment. This weight reduction occurs due to caloric loss through urinary glucose excretion and may provide additional metabolic benefits for overweight or obese diabetic patients.\nCardiovascular Benefits\nEmerging research on SGLT2 inhibitors suggests potential cardiovascular protective effects, including modest reductions in blood pressure and improvements in various cardiovascular risk markers. These benefits may be particularly valuable for diabetic patients who are at increased risk of cardiovascular disease.\nLow Risk of Hypoglycemia\nBecause REMOFLOZIN 100 works independently of insulin secretion, it carries a minimal risk of hypoglycemia when used as monotherapy. This safety profile makes it particularly suitable for elderly patients or those at higher risk of dangerous low blood sugar episodes.\nRenal Function Considerations\nThe medication may offer nephroprotective benefits by reducing intraglomerular pressure and proteinuria in diabetic patients, potentially slowing the progression of diabetic kidney disease.\nConvenient Once-Daily Dosing\nREMOFLOZIN 100's pharmacokinetic profile allows for convenient once-daily administration, improving patient compliance and treatment adherence.\nPotential Side Effects and Safety Considerations\nWhile REMOFLOZIN 100 is generally well-tolerated, patients should be aware of potential side effects:\nCommon Side Effects\n\nGenital Mycotic Infections: Increased glucose in urine may promote fungal infections, particularly in women\nUrinary Tract Infections: More frequent urination and glucose in urine may increase UTI risk\nIncreased Urination: Polyuria is expected due to the medication's mechanism of action\nThirst: Patients may experience increased thirst due to fluid loss\nDizziness: Particularly when standing up quickly, due to mild blood pressure reductions\n\nSerious but Rare Side Effects\n\nDiabetic Ketoacidosis: Although rare, euglycemic DKA has been reported with SGLT2 inhibitors\nAcute Kidney Injury: Dehydration may affect kidney function in susceptible individuals\nLower Limb Amputation: Some SGLT2 inhibitors have shown increased risk in specific populations\nHypotension: Particularly in patients on diuretics or with compromised cardiovascular function\n\nContraindications and Precautions\nREMOFLOZIN 100 should not be used in patients with type 1 diabetes, severe renal impairment, diabetic ketoacidosis, or those with known hypersensitivity to the drug. Pregnant and breastfeeding women should avoid this medication. Patients should maintain adequate hydration and practice proper genital hygiene to minimize infection risks.\nDosage and Administration Guidelines\nThe standard recommended dose is one REMOFLOZIN 100 tablet taken orally once daily, preferably at the same time each day. The medication can be taken with or without food. Patients should not double doses if they miss a scheduled dose but should take the next dose at the regular time. Dosage adjustments may be necessary based on individual response, renal function, and concomitant medications. Regular monitoring of blood glucose levels, kidney function, and HbA1c is essential for optimal treatment management.\nConclusion\nREMOFLOZIN 100 represents a valuable therapeutic advancement in type 2 diabetes management, offering patients an innovative approach to glycemic control through its unique renal mechanism of action. The medication's ability to reduce blood sugar levels while providing additional benefits such as weight loss, cardiovascular protection, and low hypoglycemia risk makes it an attractive option for many diabetic patients.", "price": 335.0, "discountamount": 101.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2301, "imageuri": "https://productimages.withfloats.com/actual/698d9191cd6033ecce84b352.png", "tileimageuri": "https://productimages.withfloats.com/tile/698d9191cd6033ecce84b352.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-12T08:38:40.037Z", "updatedon": "2026-03-13T11:02:30.281Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//remogliflozin-etabonate-tablets-100-mg/2301", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "REMOFLOZIN 100", "category": "DIABETIC RANGE", "tags": [ "Remogliflozin Etabonate 100mg tablets for type 2 diabetes", "Remogliflozin 100mg oral diabetes medication", "Remogliflozin Etabonate tablets 100mg prescription", "Remogliflozin 100 mg SGLT2 inhibitor tablets", "Remogliflozin Etabonate 100mg diabetes control tablets", "Buy Remogliflozin 100mg tablets online", "Remogliflozin Etabonate 100mg pack price", "Remogliflozin 100mg tablets for blood sugar management" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694e56c05837f90c86a7eb8c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin linagliptin and metformin", "description": "LINALIGIP EMPAMET (Empagliflozin, Linagliptin, and Metformin Hydrochloride ER Tablets) stands out as a comprehensive triple therapy for adults with type 2 diabetes mellitus, combining three synergistic agents to tackle hyperglycemia from multiple angles. This once-daily extended-release formulation simplifies adherence while delivering robust glycemic control, weight management, and cardiovascular protection. Patients often seek it for its convenience in managing blood sugar levels when diet, exercise, and single agents fall short.\n​\n\nProduct Description and Composition\nLINALIGIP EMPAMET features Empagliflozin (typically 10-25mg), Linagliptin (5 mg), and Metformin Hydrochloride ER (up to 1000mg) in a single tablet, designed for prolonged release to minimize gastrointestinal upset. Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in the kidneys, promoting its excretion via urine. Linagliptin, a DPP-4 inhibitor, enhances incretin hormones like GLP-1 to boost insulin secretion and suppress glucagon. Metformin ER reduces hepatic glucose production and improves insulin sensitivity without hypoglycemia risk.\n​\n\nThis unique blend from Steris Healthcare ensures steady drug delivery over 24 hours, reducing peak-trough fluctuations for stable HbA1c reductions of 1.5-2.0%. The extended-release metformin coats the tablet core, dissolving gradually in the intestines for better tolerability compared to immediate-release forms. Ideal for Indian patients facing rising diabetes prevalence, it addresses insulin resistance, postprandial spikes, and caloric overload holistically.\n​\n\nMechanism of Action\nThe triple mechanism targets key diabetes pathways: Empagliflozin inhibits SGLT2 in proximal renal tubules, lowering blood glucose by 70-90g daily through glycosuria, independent of insulin. Linagliptin selectively binds DPP-4, prolonging GLP-1 and GIP activity to stimulate glucose-dependent insulin release from beta cells and curb glucagon-mediated gluconeogenesis. Metformin activates AMPK in hepatocytes, inhibiting gluconeogenesis while enhancing peripheral glucose uptake.\n​\n\nSynergy amplifies effects—SGLT2 inhibition provides insulin-independent control, DPP-4 boosts prandial responses, and metformin tackles fasting hyperglycemia—resulting in complementary HbA1c drops without overlapping toxicities. Clinical data show this combination yields superior efficacy over dual therapies, with added osmotic diuresis aiding fluid balance.\n​\n\nUses and Indications\nLINALIGIP EMPAMET treats type 2 diabetes in adults, as adjunct to diet and exercise, especially when metformin alone or dual therapy inadequately controls glycemia. Primary uses include newly diagnosed patients needing intensification, those with obesity (due to weight loss from glycosuria), and high-risk cardiovascular profiles benefiting from empagliflozin's heart protection. It excels in managing postprandial hyperglycemia, fasting glucose, and preventing complications like nephropathy.\n​\n\nPrescribed for patients intolerant to other agents or requiring simplified regimens, it suits Indian demographics with high metabolic syndrome rates. Not for type 1 diabetes or ketoacidosis; renal function (eGFR >45 mL/min) guides initiation.\n​\n\nKey Benefits\nLINALIGIP EMPAMET offers multifaceted advantages for long-term diabetes management:\n\nSuperior Glycemic Control: Achieves 1.8% HbA1c reduction in trials, outperforming monotherapies by targeting multiple defects.\n​\n\nWeight Loss: Empagliflozin induces 3-5kg loss via caloric excretion, countering metformin's neutral effect.\n​\n\nCardiovascular and Renal Protection: Reduces major adverse cardiac events (MACE) by 14% and slows CKD progression, per EMPA-REG outcomes.\n​\n\nLow Hypoglycemia Risk: Glucose-dependent actions of linagliptin and empagliflozin minimize lows, unlike sulfonylureas.\n​\n\nConvenience: Single-tablet ER dosing improves compliance, vital for busy lifestyles in Jaipur and beyond.\n​\n\nBlood Pressure Reduction: Mild diuretic effect lowers systolic BP by 3-5 mmHg.\n​\n\nThese benefits enhance quality of life, reducing fatigue, neuropathy risks, and healthcare costs.\n\nSide Effects\nCommon side effects mirror individual components but occur less due to synergy:\n\nGastrointestinal: Metformin ER causes less nausea/diarrhea (10-15%) than IR forms; titrate slowly.\n​\n\nGenitourinary: Empagliflozin raises UTI/genital mycotic infection risk (5-10%), managed with hygiene.\n​\n\nVolume Depletion: Orthostatic hypotension in 2-3%, especially with diuretics.\n​\n\nSerious effects include lactic acidosis (rare, <1/100,000 with metformin in eGFR >30), ketoacidosis (euglycemic, 0.1%), and acute kidney injury. Monitor for dehydration, pancreatitis signs, or bullous pemphigoid with linagliptin. Hypersensitivity rash or bone fractures warrant discontinuation.\n​\n\nSide Effect Category\tFrequency\tManagement\nNausea and Diarrhea\tCommon (10%)\tTake with food, slow titration \n​\nUTI/Mycotic Infections\tCommon (7%)\tHydration, antifungals \n​\nHypoglycemia\tRare (<2%)\tWith insulin, dose adjust \n​\nLactic Acidosis\tVery Rare.\tAvoid in renal/hepatic failure \n​\nKetoacidosis\tRare (0.1%)\tCheck ketones if nausea \n​\nDosage and Administration\nStart with Empagliflozin 10mg/Linagliptin 5mg/Metformin ER 1000mg once daily with morning meal to optimize absorption and reduce GI effects. Titrate metformin to 2000mg max based on tolerance; empagliflozin to 25mg if needed. Swallow whole; no crushing. Adjust for renal impairment (eGFR 30-45: max metformin 1000mg; <30 contraindicated). Elderly start low due to volume sensitivity.\n​\n\nMissed dose: Take soon if less than 12 hours late; skip otherwise. Discontinue pre-surgery or contrast use.\n\nPrecautions and Warnings\nAssess eGFR before and 3-6 months after initiation; hold if <45. Caution in dehydration, heart failure, or liver disease risks lactic acidosis. Educate on ketoacidosis symptoms (nausea, fatigue) despite normal glucose. Avoid excessive alcohol; monitor BP in hypertensives. Pregnancy category D—use insulin instead. Breastfeeding is contraindicated.\n​\n\nDrug interactions: Adding sulfonylureas/insulin heightens hypoglycemia; rifampin reduces linagliptin levels; ritonavir boosts empagliflozin exposure.\n\nFrequently Asked Questions\nWhat is LINALIGIP EMPAMET used for?\nControls type 2 diabetes via triple action on glucose excretion, incretins, and insulin sensitivity.\n​\nDoes it cause weight gain?\nNo—it promotes 2-4 kg loss, unlike some antidiabetics.\n​\n\nSafe for kidneys?\nRenal-protective; monitor eGFR.\n​\n\nHypoglycemia risk?\nMinimal without sulfonylureas.\n\nConclusion\nLINALIGIP EMPAMET revolutionizes type 2 diabetes care with its potent, convenient triple therapy, delivering glycemic mastery, weight benefits, and cardioprotection unmatched by singles or duos. Backed by landmark trials, it empowers patients toward complication-free lives when integrated with lifestyle changes. Consult physicians for personalized dosing to harness its full potential safely.", "price": 220.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2257, "imageuri": "https://productimages.withfloats.com/actual/694e60c1db6d50f75e42e875.png", "tileimageuri": "https://productimages.withfloats.com/tile/694e60c1db6d50f75e42e875.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-26T09:34:56.604Z", "updatedon": "2026-03-13T10:59:31Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-linagliptin-and-metformin/2257", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "LINALIGIP EMPAMET", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 10 mg", "empagliflozin 25 mg", "empagliflozin 10 mg uses in hindi", "empagliflozin 10 mg tablet.", "type 2 diabetes mellitus.", "linagliptin", "Linagliptin 5 mg", "linagliptin 5 mg uses", "linagliptin tablet uses", "Linagliptin 5 mg price", "Empagliflozin, an SGLT2 inhibitor.", "Metformin ER reduces hepatic glucose production and improves insulin.", "LINALIGIP EMPAMET revolutionizes type 2 diabetes.", "empagliflozin linagliptin and metformin tablets", "empagliflozin linagliptin metformin combination tablet", "empagliflozin linagliptin metformin tablets uses", "empagliflozin linagliptin metformin triple combination", "empagliflozin linagliptin metformin dosage strength", "empagliflozin linagliptin metformin sustained release tablet", "empagliflozin linagliptin metformin medicine for diabetes", "empagliflozin linagliptin metformin tablet uses", "empagliflozin linagliptin metformin benefits", "empagliflozin linagliptin metformin for type 2 diabetes", "empagliflozin linagliptin metformin blood sugar control", "empagliflozin linagliptin metformin weight loss benefit", "what is empagliflozin linagliptin metformin tablet", "how does empagliflozin linagliptin metformin work", "empagliflozin linagliptin metformin tablet price in india", "empagliflozin linagliptin metformin tablet dosage", "empagliflozin linagliptin metformin before or after food" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6911af10f122e2a45d230b07", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 2 mg", "description": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg is a triple-combination oral anti-diabetic medication formulated to achieve optimal blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). This unique blend brings together three complementary agents — Sitagliptin (a DPP-4 inhibitor), Metformin (a biguanide), and Glimepiride (a sulfonylurea) — that work through distinct mechanisms to enhance glucose regulation, improve insulin sensitivity, and support overall metabolic balance.\n\nThis advanced combination therapy is prescribed when monotherapy or dual therapy fails to achieve adequate glycemic control. It helps reduce both fasting plasma glucose (FPG) and postprandial glucose (PPG) levels, promoting stable long-term glycemic management.\n\nUses of Sitagliptin + Metformin + Glimepiride\n\nThis fixed-dose combination is primarily indicated for the management of Type 2 Diabetes Mellitus in adults. It is especially beneficial for patients whose blood sugar levels remain uncontrolled despite treatment with Metformin and Glimepiride or Metformin and Sitagliptin alone.\n\nIts main objectives include:\n\nControlling elevated blood glucose levels in adults with Type 2 diabetes\n\nReducing the risk of diabetes-related complications such as neuropathy, nephropathy, and cardiovascular diseases\n\nSupporting better insulin utilization by the body\n\nComplementing diet, exercise, and lifestyle modification to maintain optimal glycemic balance\n\nMechanism of Action\n\nEach component of this combination plays a vital role in maintaining blood sugar control:\n\nSitagliptin (50 mg) – A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the activity of incretin hormones. These hormones stimulate insulin release and suppress glucagon production when blood glucose levels rise, thereby improving post-meal glucose control.\n\nMetformin Hydrochloride (1000 mg) – A biguanide that lowers glucose production in the liver and increases the body’s sensitivity to insulin. It also decreases intestinal glucose absorption, making it an essential first-line therapy in diabetes management.\n\nGlimepiride (2 mg) – A sulfonylurea that stimulates pancreatic beta cells to release more insulin, especially when blood glucose levels are high. It works synergistically with Metformin and Sitagliptin for more effective glycemic control.\n\nKey Benefits\n\nTriple Mechanism for Superior Control:\nBy combining three potent agents, the medication addresses multiple pathways of glucose regulation—insulin secretion, insulin sensitivity, and hepatic glucose output—resulting in comprehensive and consistent control of blood sugar levels.\n\nEffective Glycemic Stability:\nThe combination helps maintain target HbA1c levels and reduces both fasting and post-meal glucose spikes without significant weight gain when used with proper diet and exercise.\n\nReduced Risk of Diabetic Complications:\nLong-term blood sugar control minimizes the risk of complications such as kidney disease, vision problems, nerve damage, and heart conditions associated with uncontrolled diabetes.\n\nConvenient Fixed-Dose Formulation:\nCombining three medications into a single tablet simplifies dosing schedules, improves patient adherence, and reduces pill burden, which is crucial for long-term treatment success.\n\nImproved Insulin Efficiency:\nEnhances the body's natural insulin response and glucose metabolism, allowing for smoother daily energy levels and reduced fatigue associated with hyperglycemia.\n\nPossible Side Effects\n\nWhile this combination is generally well tolerated, some patients may experience side effects, especially at the beginning of therapy. Common and rare side effects include:\n\nHypoglycemia (low blood sugar): More likely when meals are skipped or during excessive physical exertion. Symptoms include sweating, dizziness, and rapid heartbeat.\n\nGastrointestinal disturbances: Such as nausea, vomiting, diarrhea, abdominal discomfort, or loss of appetite (mostly due to Metformin).\n\nHeadache or Weakness: Usually mild and transient.\n\nAllergic reactions: Rarely, rash or itching may occur.\n\nLactic Acidosis (rare but serious): A potential complication of Metformin, particularly in patients with kidney impairment or excessive alcohol consumption.\n\nWeight gain: Mild weight gain may occur due to Glimepiride’s insulin-enhancing effect.\n\nPrecautions:\n\nRegular monitoring of blood sugar levels and kidney function is essential.\n\nAvoid alcohol and consult a doctor before using this medicine if you have liver or kidney disease.\n\nThe medication should not be used in patients with Type 1 diabetes or diabetic ketoacidosis.\n\nConclusion\n\nThe combination of Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg represents a powerful and balanced therapy for adults with Type 2 Diabetes Mellitus, especially those requiring triple-drug intervention to achieve desired glycemic control. Its multi-targeted approach ensures effective management of both fasting and postprandial glucose levels, thereby improving long-term metabolic health and reducing the risk of complications.", "price": 295.0, "discountamount": 89.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2197, "imageuri": "https://productimages.withfloats.com/actual/6911af137e4c90e1dc453884.png", "tileimageuri": "https://productimages.withfloats.com/tile/6911af137e4c90e1dc453884.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-10T09:23:28.795Z", "updatedon": "2026-03-13T10:41:32.995Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-2-mg/2197", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+2 ", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg", "anti-diabetic medication", "blood sugar control", "Type 2 Diabetes Mellitus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "glimepiride voglibose metformin", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/69abe998ad5b8f3f9ba863c2.png", "tileimageuri": "https://productimages.withfloats.com/tile/69abe998ad5b8f3f9ba863c2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2026-03-13T10:35:41.824Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//glimepiride-voglibose-metformin/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "DIABETIC RANGE", "tags": [ "glimepiride voglibose metformin tablets", "glimepiride voglibose metformin combination", "glimepiride voglibose metformin dosage", "glimepiride voglibose metformin uses", "glimepiride voglibose metformin composition", "glimepiride voglibose metformin tablets ip", "glimepiride voglibose metformin triple combination", "glimepiride voglibose metformin for type 2 diabetes", "triple drug combination for type 2 diabetes", "diabetes medicine for high fasting and pp sugar", "medicine for uncontrolled diabetes type 2", "combination tablets for diabetes management", "combination tablets for diabetes management", "when to take glimepiride voglibose metformin tablets", "who should take glimepiride voglibose metformin", "benefits of glimepiride voglibose metformin tablets", "side effects of glimepiride voglibose metformin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66d83ad4ed345980e0fca5c5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Voglibose 0.3mg, Metformin 500mg, Gliclazide 80mg", "description": "GLICLAGLAZE TRIO 0.3 \nVoglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)\nGLICLAGLAZE TRIO 0.3 is a powerful combination medication designed to manage and control type 2 diabetes. It is formulated with three active ingredients: Voglibose, Metformin, and Gliclazide. This unique combination helps to regulate blood sugar levels effectively, providing a comprehensive approach to diabetes management. GLICLAGLAZE TRIO 0.3 is particularly useful for patients who require a multifaceted treatment strategy to keep their blood glucose levels in check.\n\nKey Benefits:\nEffective Blood Sugar Control: The combination of Voglibose, Metformin, and Gliclazide offers a synergistic effect, providing comprehensive control over blood sugar levels.\nPrevents Post-Meal Sugar Spikes: Voglibose helps in delaying glucose absorption, reducing the risk of hyperglycemia after meals.\nImproved Insulin Sensitivity: Metformin enhances the body's response to insulin, ensuring better glucose management.\nEnhanced Insulin Secretion: Gliclazide helps in stimulating insulin release from the pancreas, making it easier to maintain stable blood sugar levels.\nHow Does It Work?\nGLICLAGLAZE TRIO 0.3 works through a multi-pronged approach to manage diabetes. Voglibose slows down the absorption of carbohydrates in the gut, which helps to prevent rapid increases in blood sugar levels after meals. Metformin reduces the liver's glucose production and improves insulin sensitivity, ensuring better glucose uptake and utilization. Gliclazide stimulates the pancreas to release insulin, aiding in the reduction of blood glucose levels.\nDirections for Use:\nTake GLICLAGLAZE TRIO 0.3 as prescribed by your healthcare provider. It is typically taken before meals to maximize its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and frequency based on your individual health needs.\nSide Effects:\nLike all medications, GLICLAGLAZE TRIO 0.3 may cause some side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially if you skip meals or engage in intense physical activity. Other possible side effects include dizziness, headache, and fatigue. If you experience any severe side effects or allergic reactions, seek medical attention immediately.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 173.44, "discountamount": 52.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Key Benefits", "abdominal pain", "glucose uptake", "type 2 diabetes", "rapid increases", "insulin release", "low blood sugar", "GLICLAGLAZE TRIO", "medical attention", "glucose absorption", "allergic reactions", "appropriate dosage", "synergistic effect", "unique combination", "glucose production", "glucose management", "diabetes management", "healthcare provider", "severe side effects", "Common side effects", "blood glucose levels", "comprehensive control", "multi-pronged approach", "comprehensive approach", "Post-Meal Sugar Spikes", "individual health needs", "three active ingredients", "intense physical activity", "stable blood sugar levels", "Enhanced Insulin Secretion", "Other possible side effects", "Improved Insulin Sensitivity", "gastrointestinal disturbances", "Effective Blood Sugar Control", "powerful combination medication", "multifaceted treatment strategy", "postprandial blood sugar spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1962, "imageuri": "https://productimages.withfloats.com/actual/66d83afac7293b3595ec4ea6.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/66d83afac7293b3595ec4ea6.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-04T10:47:48.369Z", "updatedon": "2026-05-14T07:47:00.105Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//voglibose-0-3mg-metformin-500mg-gliclazide-80mg/1962", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE TRIO 0.3", "category": "DIABETIC RANGE", "tags": [ "Voglibose 0.3mg,", "Metformin 500mg", "Gliclazide 80mg", "voglibose metformin gliclazide tablet", "voglibose 0.3 metformin 500 gliclazide 80", "voglibose metformin gliclazide combination", "triple drug diabetes tablet voglibose", "voglibose gliclazide metformin tablet", "voglibose 0.3 mg metformin 500 mg gliclazide 80 mg", "voglibose metformin gliclazide fixed dose combination", "voglibose 0.3 mg triple combination tablet", "metformin 500 voglibose gliclazide tablet", "gliclazide 80 metformin voglibose tablet", "voglibose metformin gliclazide tablet for type 2 diabetes", "triple combination tablet for diabetes", "voglibose metformin gliclazide for blood sugar control", "voglibose metformin gliclazide uses", "how to take voglibose metformin gliclazide tablet", "voglibose metformin gliclazide tablet price", "voglibose metformin gliclazide manufacturer", "voglibose metformin gliclazide supplier" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662cb8e161afa2274ff6309", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.3 ", "description": "VOGLIGOLD 0.3 \nVoglibose (0.3mg)\nIntroduction to VOGLIGOLD 0.3\nVOGLIGOLD 0.3 is an oral medication designed to help manage type 2 diabetes mellitus by controlling blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor that works by slowing the digestion and absorption of carbohydrates in the intestines. This mechanism helps prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.3 is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.3mg\nVoglibose is a potent alpha-glucosidase inhibitor. It functions by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.3\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.3 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.3 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.3 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/st-gliptin-dapa-100-10-134075", "price": 119.0, "discountamount": 35.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dapa", "rise", "diet", "Order", "water", "EMAIL", "meals", "glass", "option", "timing", "Action", "adults", "gliptin", "patients", "exercise", "readings", "Low Risk", "metformin", "VOGLIGOLD", "Voglibose", "mechanism", "Guidelines", "conversion", "same times", "intestines", "one tablet", "Optimal Use", "weight gain", "combination", "information", "Adjustments", "Introduction", "Hypoglycemia", "sterisonline", "best results", "sterispharma", "sulfonylureas", "CALL/WHATSAPP", "simple sugars", "Key Component", "treatment plan", "typical dosage", "Administration", "Consistent Use", "Weight Neutral", "low blood sugar", "small intestine", "oral medication", "insulin secretion", "Regular monitoring", "Recommended Dosage", "blood sugar spikes", "effective treatment", "healthcare provider", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1518, "imageuri": "https://productimages.withfloats.com/actual/667d3145422dd0be26724c0b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3145422dd0be26724c0b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:57:50.904Z", "updatedon": "2026-03-13T06:49:01.697Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vogligold-0-3-/1518", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.3 ", "category": "DIABETIC RANGE", "tags": [ "voglibose 0.3mg price", "voglibose 0.3mg dosage", "voglibose 0.3mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662aa04db100e1fdc2dcb68", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nVILDIABATE 100 is a medication designed to manage type 2 diabetes mellitus by targeting specific aspects of glucose regulation. It contains Vildagliptin, an oral antidiabetic agent that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Vildagliptin works by inhibiting the enzyme DPP-4, which is responsible for degrading incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).\n\nHere are key points about VILDIABATE 100:\n\nMechanism of Action: Vildagliptin acts by inhibiting DPP-4, thereby increasing the levels of GLP-1 and GIP. These hormones play crucial roles in glucose metabolism:\n\nGLP-1 stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner. It also inhibits glucagon secretion, reduces appetite, and slows gastric emptying.\nGIP enhances insulin release in response to meals, contributing to postprandial glucose control.\nBlood Sugar Control: By enhancing insulin secretion and reducing glucagon levels, VILDIABATE 100 helps lower blood sugar levels, especially after meals. This mechanism targets both fasting and postprandial hyperglycemia, contributing to overall glycemic control.\n\nDosage and Administration: VILDIABATE 100 is typically taken orally once daily, preferably with a meal to maximize its effects on postprandial glucose levels. The dosage may vary depending on individual needs and response to treatment. It's essential to follow your healthcare provider's instructions regarding dosage and timing.\n\nEfficacy and Safety: Clinical studies have demonstrated the efficacy of Vildagliptin in lowering HbA1c levels (a marker of long-term glucose control) and improving glycemic parameters. It is generally well-tolerated, with common side effects including headache, nasopharyngitis (inflammation of the nose and throat), and upper respiratory tract infections. Serious side effects are rare but may include pancreatitis or hypersensitivity reactions.\n\nCombination Therapy: VILDIABATE 100 may be prescribed as monotherapy or in combination with other antidiabetic medications such as metformin or sulfonylureas. Combining medications with different mechanisms of action can provide synergistic benefits in managing diabetes.\n\nMonitoring and Follow-Up: Regular monitoring of blood sugar levels, kidney function, and other relevant parameters is important during treatment with VILDIABATE 100. Your healthcare provider may adjust the dosage or add/modify other medications based on your response and individual needs.\n\nLifestyle Modifications: In addition to medication, lifestyle modifications such as a healthy diet, regular exercise, weight management, and avoiding tobacco and excessive alcohol intake are essential components of diabetes management.\n\nIn conclusion, VILDIABATE 100 containing Vildagliptin is an effective oral antidiabetic medication that helps regulate blood sugar levels in patients with type 2 diabetes. It acts by enhancing insulin secretion and reducing postprandial glucose levels, contributing to improved glycemic control. However, it should be used under medical supervision, and adherence to prescribed dosage and lifestyle recommendations is crucial for optimal diabetes management.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452\n\n\n\n\n\n", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "nose", "GLP-1", "EMAIL", "class", "meals", "Order", "timing", "throat", "enzyme", "Safety", "Dosage", "marker", "tobacco", "fasting", "response", "addition", "appetite", "headache", "patients", "Efficacy", "metformin", "Follow-Up", "adherence", "treatment", "VILDIABATE", "conclusion", "key points", "information", "monotherapy", "healthy diet", "instructions", "sterisonline", "pancreatitis", "inflammation", "sterispharma", "HbA1c levels", "CALL/WHATSAPP", "sulfonylureas", "crucial roles", "Administration", "insulin release", "nasopharyngitis", "kidney function", "glucagon levels", "gastric emptying", "specific aspects", "Clinical studies", "individual needs", "regular exercise", "other medications", "Vildagliptin acts", "incretin hormones", "DPP-4) inhibitors", "weight management", "insulin secretion", "glucose metabolism", "glucose regulation", "glucagon secretion", "blood sugar levels", "Regular monitoring", "Combination Therapy", "glycemic parameters", "common side effects", "Blood Sugar Control", "medical supervision", "healthcare provider", "essential components", "synergistic benefits", "different mechanisms", "Serious side effects", "pancreatic beta cells", "dipeptidyl peptidase-4", "oral antidiabetic agent", "Lifestyle Modifications", "glucose-dependent manner", "excessive alcohol intake", "overall glycemic control", "type 2 diabetes mellitus", "lifestyle recommendations", "other relevant parameters", "long-term glucose control", "hypersensitivity reactions", "postprandial hyperglycemia", "optimal diabetes management", "postprandial glucose levels", "postprandial glucose control", "other antidiabetic medications", "upper respiratory tract infections", "effective oral antidiabetic medication", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1491, "imageuri": "https://productimages.withfloats.com/actual/6662aa0b364f23242470b3ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662aa0b364f23242470b3ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:34:44.056Z", "updatedon": "2026-03-13T06:44:28.496Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-100-/1491", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE 100", "Vildagliptin (100mg)", "Vildagliptin 100 mg uses", "Vildagliptin 100 mg price", "Vildagliptin 100 mg SR brand Name", "Vildagliptin 100 mg brands in India", "", "Vildagliptin 100 mg generic medicine", "Vildagliptin 100 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661afd366170d1ff8cb4626", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide 60mg SR Pioglitazone 15mg Metformin HCL 500mgSR", "description": "TRIGLICLAGLAZE 60 \nGliclazide 60mg (SR), pioglitazone 15 mg, and metformin HCl 500 mg (SR)\nTRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action.\n\nGliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells.\n\nPioglitazone 15 mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management.\n\nMetformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract.\n\nKey Benefits of TRIGLICLAGLAZE 60:\nComprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day.\n\nStimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes.\n\nReduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization.\n\nExtended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia.\n\nDosage and Administration:\nTRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects.\nDosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions.\nFor further information:\nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "SR", "day", "risk", "meals", "Order", "liver", "EMAIL", "gradual", "fasting", "pancreas", "Enhanced", "treatment", "fat cells", "absorption", "information", "medications", "muscle cells", "Pioglitazone", "sterisonline", "Key Benefits", "hypoglycemia", "instructions", "sterispharma", "postprandial", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "Administration", "glucose uptake", "TRIGLICLAGLAZE", "common feature", "glucose spikes", "insulin action", "insulin release", "Gliclazide 60mg", "digestive tract", "multiple aspects", "prolonged release", "Dosage adjustments", "peripheral tissues", "blood sugar levels", "glucose production", "insulin resistance", "glucose regulation", "distinct mechanisms", "healthcare provider", "individual response", "glucose utilization", "insulin sensitivity", "three key components", "biguanide medication", "comprehensive control", "combination medication", "sulfonylurea medication", "thiazolidinedione class", "overall glucose control", "type 2 diabetes mellitus", "Extended Release Formulation", "Comprehensive Glucose Control", "gastrointestinal side effects", "sustained-release formulations", "consistent blood sugar control", "efficient blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1485, "imageuri": "https://productimages.withfloats.com/actual/6661afd7f21358d53af3cd71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661afd7f21358d53af3cd71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:47:15.16Z", "updatedon": "2026-03-13T07:32:49.604Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclazide-60mg-sr-pioglitazone-15mg-metformin-hcl-500mgsr/1485", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 60 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 60", "Gliclazide 60mg (SR)", "Pioglitazone 15mg", "Metformin HCL 500mg(SR)", "Metformin SR 500mg uses", "Metformin SR 500 price", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }